 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockNews.com upgraded shares of Concert Pharmaceuticals (NASDAQ:CNCE Get Rating) from a sell rating to a hold rating in a report released on Saturday. Other research analysts have also issued research reports about the company. Truist Financial lowered Concert Pharmaceuticals from a buy rating to a...

Concert Pharmaceuticals (NASDAQ:CNCE) Upgraded to "Hold" at StockNews.com

Concert Pharmaceuticals (NASDAQ:CNCE  Get Rating) was upgraded by research analysts at StockNews.com from a sell rating to a hold rating in a report issued on Saturday. CNCE has been the topic of a number of other reports. Truist Financial lowered shares of Concert...

StockNews.com Upgrades Concert Pharmaceuticals (NASDAQ:CNCE) to "Hold"

Point72 Asset Management L.P. acquired a new position in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE Get Rating) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 270,600 shares of the ...

Point72 Asset Management L.P. Invests $1.81 Million in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE  Get Rating) saw a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 1,080,000 shares, a decline of 58.5% from the January 31st total of 2,600,000 shares. Based on an average daily ...

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Short Interest Update

StockNews.com lowered shares of Concert Pharmaceuticals (NASDAQ:CNCE  Get Rating) from a hold rating to a sell rating in a research note published on Friday. Several other research firms also recently issued reports on CNCE. Jonestrading reiterated a hold rating on shares of Concert ...

Concert Pharmaceuticals (NASDAQ:CNCE) Downgraded by StockNews.com

StockNews.com lowered shares of Concert Pharmaceuticals (NASDAQ:CNCE Get Rating) from a hold rating to a sell rating in a research note published on Friday. Several other research firms also recently issued reports on CNCE. Jonestrading reiterated a hold rating on shares of Concert Pharmaceuticals ...

This is a signal that CNCE's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Concert Pharmaceuticals (CNCE, $8.4) RSI Indicator left the overbought zone on February 22, 2023

Concert Pharmaceuticals (CNCE, $8.35) RSI Indicator left the overbought zone on February 21, 2023

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE  Get Rating) insider Jeffrey A. Munsie sold 3,762 shares of the businesss stock in a transaction that occurred on Wednesday, February 15th. The stock was sold at an average price of $8.34, for a total value of $31,375.08. Following the sale, ...

Insider Selling: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insider Sells $31,375.08 in Stock

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE  Get Rating) COO Nancy Stuart sold 6,048 shares of the firms stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $8.33, for a total transaction of $50,379.84. Following the sale, the chief operating...

Nancy Stuart Sells 6,048 Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Stock

Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.

Market Cap	$401.95M
52-Wk High	$8.55
52-Wk Low	$2.66

Current Price	$8.39
Prev Close	$8.36
Open	$8.36
Dividend Yield	N/A
50-Day Moving Average	$7.57
Beta	0.88
Avg. Volume	1.34M
PE Ratio	-2.61

52-Week High	$8.55
52-Week Low	$2.66
Market Capitalization	$401.95M
EPS	-$3.21
Price to Book	3.01
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-1.61

CNCE Concert Pharmaceuticals Inc

About

Feed

News

Fundamentals